CRISPR-based Gene Editing Market Size, Share & Trends Analysis Report By Product & Service (CRISPR Kits & Reagents), By Application (Biomedical, Agricultural), By End Use, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Cranial Implants Market Growth & Trends
The global cranial implants market size is anticipated to reach USD 2.09 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.5% from 2024 to 2030. Increasing cases of brain cancer and traumas such as malignant brain tumor is anticipated to boost the growth. For instance, according to the American Cancer Society, in 2019, 23,820 people were diagnosed with brain tumor.
One of the major causes of brain tumor is abnormal changes that occur in normal brain cells that may lead to formation of brain tumors. Brain tumor is classified into benign which is non-cancerous and malignant tumors which are cancerous. Prevalence of malignant tumor is witnessing a rise in U.S. owing to the factors such as unhealthy lifestyle and genetic disorders.
Technological advancements such as 3D printing, cranial implant fabrication through computer aided design/computer aided manufacturing modeling, regeneration of larger bone defects through tissue engineering therapies plays a vital role in fueling market growth. For instance, Renishaw plc, launched its metal 3D printing craniomaxillofacial implants which produces complex shapes that are not possible with traditional machining method.
Cranial Implants Market Report Highlights
Cranial Implants Market Growth & Trends
The global cranial implants market size is anticipated to reach USD 2.09 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.5% from 2024 to 2030. Increasing cases of brain cancer and traumas such as malignant brain tumor is anticipated to boost the growth. For instance, according to the American Cancer Society, in 2019, 23,820 people were diagnosed with brain tumor.
One of the major causes of brain tumor is abnormal changes that occur in normal brain cells that may lead to formation of brain tumors. Brain tumor is classified into benign which is non-cancerous and malignant tumors which are cancerous. Prevalence of malignant tumor is witnessing a rise in U.S. owing to the factors such as unhealthy lifestyle and genetic disorders.
Technological advancements such as 3D printing, cranial implant fabrication through computer aided design/computer aided manufacturing modeling, regeneration of larger bone defects through tissue engineering therapies plays a vital role in fueling market growth. For instance, Renishaw plc, launched its metal 3D printing craniomaxillofacial implants which produces complex shapes that are not possible with traditional machining method.
Cranial Implants Market Report Highlights
- Customized cranial implants segment led the market in 2023, attributed to the increasing number of patients suffering from brain defects due to brain tumor and traumatic brain injuries
- Hospitals led the cranial implants market with the highest revenue share in 2023 due to the factors such as availability of skilled neurosurgeons and improving healthcare infrastructure in the developing countries
- Polymer segment holds the major market share owing to increasing usage of polymer in cranioplasty surgical procedure for treatment of skull defects and brain tumor
- North America led the market with the highest revenue share in 2023 owing to the adoption of technological advanced products, government initiatives, and increasing disposable income of the individuals
- Key players opt for technologically enhanced products to gain a competitive edge. For instance, in 2017 Stryker launched its CUSTOMIZED PEEK IMPLANTS. Polyether ether ketone is an organic thermoplastic polymer specially designed and manufactured according to 3D medical imaging. It also offers anesthetic correction in the cranial area
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product & Service Segment
1.2.2. Application Segment
1.2.3. End-use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. CRISPR-BASED GENE EDITING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of genetic disorders
3.2.1.2. Growing investments in biotechnology and healthcare research
3.2.1.3. Advancements in CRISPR technology and applications
3.2.2. Market restraint analysis
3.2.2.1. Ethical concerns surrounding gene editing
3.2.2.2. High costs associated with CRISPR research and development
3.3. CRISPR-based Gene Editing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. CRISPR-BASED GENE EDITING MARKET: PRODUCT & SERVICE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global CRISPR-based Gene Editing Market Product & Service Movement Analysis
4.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
4.4. Products
4.4.1. Products market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. CRISPR Kits & Reagents
4.4.2.1. CRISPR kits & reagents market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. CRISPR Libraries
4.4.3.1. CRISPR libraries market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. CRISPR-BASED GENE EDITING MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global CRISPR-based Gene Editing Market Application Movement Analysis
5.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Biomedical
5.4.1. Biomedical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Therapeutic Development
5.4.2.1. Therapeutic development market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2. By Indication
5.4.2.2.1. Genetic Disorders
5.4.2.2.1.1. Genetic Disorders market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2.2. Oncology
5.4.2.2.2.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2.3. Ophthalmology
5.4.2.2.3.1. Ophthalmology market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2.4. Others
5.4.2.2.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.3. By Delivery Method
5.4.2.3.1. Ex Vivo
5.4.2.3.2. Ex vivo market estimates and forecasts, 2018 to 2030 (USD Million
5.4.2.3.3. In Vivo
5.4.2.3.4. In vivo market estimates and forecasts, 2018 to 2030 (USD Million
5.4.3. Disease Diagnostics
5.4.3.1. Disease diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Agricultural applications
5.5.1. Agricultural applications market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.2. Plant Engineering
5.5.2.1. Plant engineering market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.3. Farm Animals Engineering
5.5.3.1. Farm animals engineering market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.4. Others
5.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. CRISPR-BASED GENE EDITING MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Global CRISPR-based Gene Editing Market End-use Movement Analysis
6.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Contract Research Organizations
6.6.1. Contract research organizations market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. CRISPR-BASED GENE EDITING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Target disease prevalence
7.4.2.4. Regulatory framework
7.4.2.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Target disease prevalence
7.4.3.4. Regulatory framework
7.4.3.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Target disease prevalence
7.4.4.4. Regulatory framework
7.4.4.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. Europe market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Target disease prevalence
7.5.2.4. Regulatory framework
7.5.2.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Target disease prevalence
7.5.3.4. Regulatory framework
7.5.3.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Target disease prevalence
7.5.4.4. Regulatory framework
7.5.4.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Target disease prevalence
7.5.5.4. Regulatory framework
7.5.5.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Target disease prevalence
7.5.6.4. Regulatory framework
7.5.6.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Target disease prevalence
7.5.7.4. Regulatory framework
7.5.7.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key country dynamics
7.5.8.2. Competitive scenario
7.5.8.3. Target disease prevalence
7.5.8.4. Regulatory framework
7.5.8.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key country dynamics
7.5.9.2. Competitive scenario
7.5.9.3. Target disease prevalence
7.5.9.4. Regulatory framework
7.5.9.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Target disease prevalence
7.6.2.4. Regulatory framework
7.6.2.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. China
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Target disease prevalence
7.6.3.4. Regulatory framework
7.6.3.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Competitive scenario
7.6.4.3. Target disease prevalence
7.6.4.4. Regulatory framework
7.6.4.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key country dynamics
7.6.5.2. Competitive scenario
7.6.5.3. Target disease prevalence
7.6.5.4. Regulatory framework
7.6.5.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key country dynamics
7.6.6.2. Competitive scenario
7.6.6.3. Target disease prevalence
7.6.6.4. Regulatory framework
7.6.6.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Competitive scenario
7.6.7.3. Target disease prevalence
7.6.7.4. Regulatory framework
7.6.7.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Target disease prevalence
7.7.2.4. Regulatory framework
7.7.2.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Target disease prevalence
7.7.3.4. Regulatory framework
7.7.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. MEA market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Competitive scenario
7.8.2.3. Target disease prevalence
7.8.2.4. Regulatory framework
7.8.2.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Competitive scenario
7.8.3.3. Target disease prevalence
7.8.3.4. Regulatory framework
7.8.3.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Competitive scenario
7.8.4.3. Target disease prevalence
7.8.4.4. Regulatory framework
7.8.4.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Competitive scenario
7.8.5.3. Target disease prevalence
7.8.5.4. Regulatory framework
7.8.5.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. List of Key Buyers for CRISPR-based Gene Editing Products & Services
8.5. Company Profiles/Listing
8.5.1. Revvity, Inc.
8.5.1.1. Company overview
8.5.1.2. Financial performance
8.5.1.3. Product/Service benchmarking
8.5.1.4. Strategic initiatives
8.5.2. Danaher Corporation
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Product/Service benchmarking
8.5.2.4. Strategic initiatives
8.5.3. GenScript
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Product/Service benchmarking
8.5.3.4. Strategic initiatives
8.5.4. Merck KGaA
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Product/Service benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Thermo Fisher Scientific, Inc.
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Product/Service benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Tocris Bioscience
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Product/Service benchmarking
8.5.6.4. Strategic initiatives
8.5.7. OriGene Technologies, Inc.
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product/Service benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Bio-Rad Laboratories
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product/Service benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Bio-Techne
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product/Service benchmarking
8.5.9.4. Strategic initiatives
8.5.10. New England Biolabs, Inc.
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product/Service benchmarking
8.5.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product & Service Segment
1.2.2. Application Segment
1.2.3. End-use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. CRISPR-BASED GENE EDITING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of genetic disorders
3.2.1.2. Growing investments in biotechnology and healthcare research
3.2.1.3. Advancements in CRISPR technology and applications
3.2.2. Market restraint analysis
3.2.2.1. Ethical concerns surrounding gene editing
3.2.2.2. High costs associated with CRISPR research and development
3.3. CRISPR-based Gene Editing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. CRISPR-BASED GENE EDITING MARKET: PRODUCT & SERVICE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global CRISPR-based Gene Editing Market Product & Service Movement Analysis
4.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
4.4. Products
4.4.1. Products market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. CRISPR Kits & Reagents
4.4.2.1. CRISPR kits & reagents market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. CRISPR Libraries
4.4.3.1. CRISPR libraries market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. CRISPR-BASED GENE EDITING MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global CRISPR-based Gene Editing Market Application Movement Analysis
5.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Biomedical
5.4.1. Biomedical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Therapeutic Development
5.4.2.1. Therapeutic development market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2. By Indication
5.4.2.2.1. Genetic Disorders
5.4.2.2.1.1. Genetic Disorders market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2.2. Oncology
5.4.2.2.2.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2.3. Ophthalmology
5.4.2.2.3.1. Ophthalmology market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2.4. Others
5.4.2.2.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.3. By Delivery Method
5.4.2.3.1. Ex Vivo
5.4.2.3.2. Ex vivo market estimates and forecasts, 2018 to 2030 (USD Million
5.4.2.3.3. In Vivo
5.4.2.3.4. In vivo market estimates and forecasts, 2018 to 2030 (USD Million
5.4.3. Disease Diagnostics
5.4.3.1. Disease diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Agricultural applications
5.5.1. Agricultural applications market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.2. Plant Engineering
5.5.2.1. Plant engineering market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.3. Farm Animals Engineering
5.5.3.1. Farm animals engineering market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.4. Others
5.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. CRISPR-BASED GENE EDITING MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Global CRISPR-based Gene Editing Market End-use Movement Analysis
6.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Contract Research Organizations
6.6.1. Contract research organizations market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. CRISPR-BASED GENE EDITING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Target disease prevalence
7.4.2.4. Regulatory framework
7.4.2.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Target disease prevalence
7.4.3.4. Regulatory framework
7.4.3.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Target disease prevalence
7.4.4.4. Regulatory framework
7.4.4.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. Europe market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Target disease prevalence
7.5.2.4. Regulatory framework
7.5.2.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Target disease prevalence
7.5.3.4. Regulatory framework
7.5.3.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Target disease prevalence
7.5.4.4. Regulatory framework
7.5.4.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Target disease prevalence
7.5.5.4. Regulatory framework
7.5.5.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Target disease prevalence
7.5.6.4. Regulatory framework
7.5.6.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Target disease prevalence
7.5.7.4. Regulatory framework
7.5.7.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key country dynamics
7.5.8.2. Competitive scenario
7.5.8.3. Target disease prevalence
7.5.8.4. Regulatory framework
7.5.8.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key country dynamics
7.5.9.2. Competitive scenario
7.5.9.3. Target disease prevalence
7.5.9.4. Regulatory framework
7.5.9.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Target disease prevalence
7.6.2.4. Regulatory framework
7.6.2.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. China
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Target disease prevalence
7.6.3.4. Regulatory framework
7.6.3.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Competitive scenario
7.6.4.3. Target disease prevalence
7.6.4.4. Regulatory framework
7.6.4.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key country dynamics
7.6.5.2. Competitive scenario
7.6.5.3. Target disease prevalence
7.6.5.4. Regulatory framework
7.6.5.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key country dynamics
7.6.6.2. Competitive scenario
7.6.6.3. Target disease prevalence
7.6.6.4. Regulatory framework
7.6.6.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Competitive scenario
7.6.7.3. Target disease prevalence
7.6.7.4. Regulatory framework
7.6.7.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Target disease prevalence
7.7.2.4. Regulatory framework
7.7.2.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Target disease prevalence
7.7.3.4. Regulatory framework
7.7.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. MEA market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Competitive scenario
7.8.2.3. Target disease prevalence
7.8.2.4. Regulatory framework
7.8.2.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Competitive scenario
7.8.3.3. Target disease prevalence
7.8.3.4. Regulatory framework
7.8.3.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Competitive scenario
7.8.4.3. Target disease prevalence
7.8.4.4. Regulatory framework
7.8.4.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Competitive scenario
7.8.5.3. Target disease prevalence
7.8.5.4. Regulatory framework
7.8.5.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. List of Key Buyers for CRISPR-based Gene Editing Products & Services
8.5. Company Profiles/Listing
8.5.1. Revvity, Inc.
8.5.1.1. Company overview
8.5.1.2. Financial performance
8.5.1.3. Product/Service benchmarking
8.5.1.4. Strategic initiatives
8.5.2. Danaher Corporation
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Product/Service benchmarking
8.5.2.4. Strategic initiatives
8.5.3. GenScript
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Product/Service benchmarking
8.5.3.4. Strategic initiatives
8.5.4. Merck KGaA
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Product/Service benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Thermo Fisher Scientific, Inc.
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Product/Service benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Tocris Bioscience
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Product/Service benchmarking
8.5.6.4. Strategic initiatives
8.5.7. OriGene Technologies, Inc.
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product/Service benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Bio-Rad Laboratories
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product/Service benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Bio-Techne
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product/Service benchmarking
8.5.9.4. Strategic initiatives
8.5.10. New England Biolabs, Inc.
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product/Service benchmarking
8.5.10.4. Strategic initiatives
